东亚药业(605177) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥352,582,674.10, representing a decrease of 4.63% compared to the same period last year[5] - The net profit attributable to shareholders for Q1 2024 was ¥24,039,198.04, an increase of 3.53% year-on-year[5] - The basic earnings per share for Q1 2024 was ¥0.21, reflecting a growth of 5.00%[5] - The diluted earnings per share decreased by 20.00% to ¥0.16 in Q1 2024[5] - Total operating revenue for Q1 2024 was ¥352.58 million, a decrease of 4.0% from ¥369.70 million in Q1 2023[17] - Net profit for Q1 2024 was ¥24.04 million, an increase of 3.5% compared to ¥23.22 million in Q1 2023[18] - The company reported a basic earnings per share of ¥0.21 for Q1 2024, compared to ¥0.20 in Q1 2023[18] Assets and Liabilities - Total assets at the end of Q1 2024 amounted to ¥3,391,314,458.01, an increase of 1.43% from the end of the previous year[6] - As of March 31, 2024, the total current assets amounted to RMB 1,613,225,625.69, a decrease of 7.67% from RMB 1,747,057,854.71 on December 31, 2023[12] - Total non-current assets reached RMB 1,778,088,832.32, an increase of 11.36% from RMB 1,596,287,447.11[13] - The total assets of the company as of March 31, 2024, were RMB 3,391,314,458.01, compared to RMB 3,343,345,301.82 at the end of 2023[14] - Total liabilities increased to RMB 1,376,301,652.38, up from RMB 1,328,072,150.07, reflecting a growth of 3.67%[14] - The company's equity attributable to shareholders was RMB 2,015,012,805.63, slightly down from RMB 2,015,273,151.75[14] Cash Flow - The net cash flow from operating activities for Q1 2024 was negative at -¥97,089,771.88, which is not applicable for comparison[5] - Cash flow from operating activities showed a net outflow of ¥97.09 million in Q1 2024, compared to a net outflow of ¥76.56 million in Q1 2023[20] - Cash flow from investing activities generated a net inflow of ¥18.28 million in Q1 2024, a significant improvement from a net outflow of ¥43.58 million in Q1 2023[21] - Cash flow from financing activities resulted in a net inflow of ¥43.40 million in Q1 2024, down from ¥56.44 million in Q1 2023[21] - The ending cash and cash equivalents balance for Q1 2024 was ¥665.96 million, an increase from ¥437.62 million in Q1 2023[21] Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,432[10] - The largest shareholder, Chi Zhengming, holds 41.48% of the shares, totaling 47,116,769 shares[10] Operational Metrics - The weighted average return on net assets was 1.19%, a decrease of 0.06 percentage points compared to the end of the previous year[6] - Accounts receivable increased significantly to RMB 216,298,957.63, up 53.73% from RMB 140,782,808.64 in the previous period[12] - Inventory decreased to RMB 595,135,979.13, down 4.45% from RMB 621,057,626.76[12] - Short-term borrowings rose to RMB 130,122,238.88, an increase of 8.77% from RMB 120,065,999.99[13] - The company reported a significant increase in accounts payable, which rose to RMB 324,192,874.45, up 15.32% from RMB 280,988,965.78[13] Research and Development - Research and development expenses rose to ¥19.28 million in Q1 2024, up 35.4% from ¥14.25 million in Q1 2023[17] - The company has not reported any new product developments or market expansion strategies in this quarter[12] Operating Costs - Total operating costs decreased to ¥326.66 million in Q1 2024, down 3.1% from ¥337.14 million in Q1 2023[17] - The company experienced a decrease in sales expenses to ¥2.67 million in Q1 2024, down 13.8% from ¥3.09 million in Q1 2023[17] Non-recurring Items - Non-recurring gains and losses for the period totaled ¥3,662,618.15 after tax[8]